COMPLETED

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.

Official Title

Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning

Quick Facts

Study Start:2021-07-01
Study Completion:2025-03-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05073692

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Romain S. Neugebauer, PhD
PRINCIPAL_INVESTIGATOR
Kaiser Permanente
Patrick J O'Connor, MD, MA, MPH
PRINCIPAL_INVESTIGATOR
HealthPartners Institute

Study Locations (Sites)

Kaiser Permanente Southern California
Pasadena, California, 91101
United States
Romain S. Neugebauer
Pleasanton, California, 94588
United States
Kaiser Permanente Hawaii
Honolulu, Hawaii, 96817
United States
Henry Ford Health System
Detroit, Michigan, 48202
United States
HealthPartners Institute
Bloomington, Minnesota, 55425
United States
Geisinger
Danville, Pennsylvania, 17821
United States

Collaborators and Investigators

Sponsor: Kaiser Permanente

  • Romain S. Neugebauer, PhD, PRINCIPAL_INVESTIGATOR, Kaiser Permanente
  • Patrick J O'Connor, MD, MA, MPH, PRINCIPAL_INVESTIGATOR, HealthPartners Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-01
Study Completion Date2025-03-12

Study Record Updates

Study Start Date2021-07-01
Study Completion Date2025-03-12

Terms related to this study

Keywords Provided by Researchers

  • Type 2 Diabetes Mellitus
  • Cardiovascular Diseases
  • Medication
  • Treatment

Additional Relevant MeSH Terms

  • Type 2 Diabetes Mellitus
  • Cardiovascular Diseases